CASP1 and hepatocellular carcinoma: In 2020, Brocker and colleagues demonstrated that the proliferator-activated receptor (PPAR)-Gm15441 lncRNA axis downregulates NLRP3 activation, and Caspase-1 and IL-β cleavage, controlling inflammation-driven HCC [138].